Author: Customer Service

Eimskip’s Financial Calendar 2026Management financial results for 2025    28. January 2026Fourth quarter 2025, Financial results for 2025 and sustainability statement 3 March 2026Annual General Meeting 2026 26 March 2026First quarter 2026                                      5 May 2026Second quarter 2026                                   25 August 2026Third quarter 2026                                    13 November 2026Management financial results for 2026    2 February 2027Fourth quarter 2026, Financial results for 2026 and sustainability statement 9 March 2027Annual General Meeting 2027 1 April 2027Financial results will be disclosed and published after market closing.Please note that dates are subject to change. For further information please contact Guðbjörg Birna Björnsdóttir,...

Miami, FL, Dec. 08, 2025 (GLOBE NEWSWIRE) — Tecnoglass, Inc. (NYSE: TGLS) (“Tecnoglass” or the “Company”), a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets, today announced that the Company will attend the Raymond James 2025 TMT & Consumer Conference in New York, NY on Wednesday, December 10, 2025. About Tecnoglass Tecnoglass Inc. is a leading producer of high-end aluminum and vinyl windows and architectural glass serving the multi-family, single-family, and commercial end markets. Tecnoglass is the second largest glass fabricator serving the U.S. and the #1 architectural glass transformation company in Latin America. Located in Barranquilla, Colombia, the Company’s 5.8 million square foot, vertically integrated,...

MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a newly published study in Translational Vision Science & Technology (TVST) examining the thermal dynamics of transscleral laser treatments for glaucoma.1 Led by Tomas M. Grippo, MD, of the Grippo Glaucoma & Cataract Center (Buenos Aires, Argentina), the study provides the first quantitative computer model comparing the thermal tissue effects of continuous wave transscleral cyclophotocoagulation (CW-TSCPC) and transscleral laser therapy using MicroPulse® technology (MicroPulse TLT) with Iridex’s Cyclo G6® Laser, G-Probe® and MicroPulse P3® delivery...

NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Bimini Capital Management, Inc. (OTCQX: BMNM), an asset manager that speacilizes in residential mortgage-related securities, has qualified to trade on the OTCQX® Best Market. Bimini Capital Management, Inc. upgraded to OTCQX from the OTCQB® Venture Market. Bimini Capital Management, Inc. begins trading today on OTCQX under the symbol “BMNM.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. The OTCQX Market provides investors with a premium U.S. public market to research and trade the shares of investor-focused companies. Graduating to the OTCQX Market marks an important milestone...

ANDOVER, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a global technology company that delivers mission-critical processing to the edge, will participate in this week’s Association of Old Crows (AOC) International Symposium and Convention, showcasing the company’s expanding portfolio of electronic warfare (EW) capabilities and sharing key insights during conference sessions. AOC 2025 is the premier event for electronic warfare, electromagnetic spectrum operations, cyber-electromagnetic activities, and information operations professionals from around the world. During the symposium, Mercury leaders will explore this year’s theme, Charting a Path to 2035: Navigating the Future of Electromagnetic Spectrum Operations.Dr. Bill Conley, Mercury’s Chief Technology Officer, will participate...

Represents first contract under Approved Supplier Status with Global Aerospace Leader MONTREAL, Dec. 08, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today the recent signing of a half-tonne contract with a Global Aerospace Leader for the supply of titanium metal powder produced by PyroGenesis’ NexGen™ plasma atomization process. This contract was achieved as part of a competitive bid process, and represents the first order received since official supplier status was granted to PyroGenesis by the client after a multi-year certification process. The contract is for the supply of “coarse” cut Ti64 powder (particle size:...

Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled hypertension in patients indicated for a pacemakerNEW HOPE, Pa., Dec. 08, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced three presentations at the 2025 Innovation in Cardiology Intervention (“ICI”) meeting in Tel Aviv, Israel, including two presentations focused on Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) and one focused on Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”). The AVIM Therapy presentations...

KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis (AD) patients KT-621 achieved strong reductions in disease-relevant Type 2 biomarkers in blood, including TARC (median reduction of 74% in patients with baseline TARC levels comparable to dupilumab AD studies), Eotaxin-3, IL-31, IgE, and in core Type 2 inflammation and AD disease-relevant gene sets in skin lesions Robust clinical activity was observed across all disease endpoints measured including mean 63% EASI reduction and mean 40% peak pruritus NRS reduction for all patients Patients with comorbid asthma showed a median 56% reduction in FeNO and meaningful improvements in asthma control, and those...

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti’s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025. Details of the presentation can be found below. Presenter: Mark Erlander, PhD (CEO) Date: 12/11/2025Time: 4:00 PM ET Interested parties can register for and access the live webcast for the conferences by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation. About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition,...